ReviewFrontiers in cell and developmental biology2026
Crosstalk of extracellular vesicles in maternal-fetal interaction.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) have emerged as key mediators of intercellular communication at the maternal-fetal interface and play indispensable roles in the establishment and maintenance of pregnancy. This review provides a mechanistic perspective on how EV-mediated signaling coordinates physiological maternal-fetal communication and how disruption of these signaling networks contributes to pregnancy-related disorders. We summarize current evidence demonstrating that EVs regulate multiple complementary biological processes, including maternal immune tolerance, trophoblast adhesion and invasion, placental angiogenesis and vascular remodeling, epithelial-stromal crosstalk, and metabolic and inflammatory adaptation, thereby maintaining maternal-fetal homeostasis. We further discuss how dysregulated EV biogenesis, cargo composition, and intercellular communication contribute to the pathogenesis of preeclampsia, gestational diabetes mellitus, preterm birth, recurrent implantation failure, and fetal growth restriction. In addition, the potential applications of EV-associated molecules as non-invasive biomarkers and the emerging use of engineered EVs for targeted therapeutic delivery are critically evaluated. Particular emphasis is placed on current challenges that limit clinical translation, including methodological heterogeneity, lack of standardized isolation and characterization protocols, insufficient biomarker validation, and pregnancy-specific safety considerations. Overall, a deeper understanding of EV-mediated maternal-fetal communication, together with methodological standardization and rigorous clinical validation, will facilitate the development of reliable EV-based diagnostic and therapeutic strategies for pregnancy-related disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.